0.793

2.81% 0.0217

After Hours: .82 0.027 +3.40%

Rani Therapeutics Holdings Inc (RANI)

Overview News Price History Option Chain Financials Discussions Forecast

Rani Therapeutics Holdings Inc stock is traded at $0.793, with a volume of 949.61K. It is up +2.81% in the last 24 hours and down -4.40% over the past month. Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Previous Close:

$0.7713

Open:

$0.7642

24h Volume:

949.61K

Relative Volume:

0.94

Market Cap:

$89.12M

Revenue:

$3.17M

Net Income/Loss:

$-36.23M

P/E Ratio:

-1.9398

EPS:

-0.4088

Net Cash Flow:

$-17.11M

1W Performance:

+3.70%

1M Performance:

-4.40%

6M Performance:

-42.54%

1Y Performance:

+48.11%

1-Day Range:

$0.76

$0.8277

1-Week Range:

$0.7477

$0.8277

52-Week Range:

$0.387

$3.87

Rani Therapeutics Holdings Inc Stock (RANI) Company Profile

Name

Rani Therapeutics Holdings Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(408) 457-3700

Address

2051 RINGWOOD AVENUE, SAN JOSE

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

RANI's Discussions on Twitter

Compare RANI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RANI Rani Therapeutics Holdings Inc	0.793	85.46M	3.17M	-36.23M	-17.11M	-0.4088
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Lake Street	Buy
Aug-02-24	Initiated	Oppenheimer	Outperform
Jun-14-24	Initiated	Maxim Group	Buy
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Oct-11-22	Initiated	UBS	Buy
Jul-27-22	Initiated	H.C. Wainwright	Buy
Jun-13-22	Initiated	Wedbush	Outperform

View All

Rani Therapeutics Holdings Inc Stock (RANI) Latest News

Jun 30, 2026

Rani Therapeutics | 8-K: Current report - Moomoo

Jun 30, 2026

Rani Therapeutics Appoints Nicholas Maestas as New Chief Financial Officer Effective June 29, 2026 - Minichart

Jun 30, 2026

New Rani Therapeutics (NASDAQ: RANI) CFO granted options, 2026 inducement plan - Stock Titan

Jun 30, 2026

Jun 29, 2026

Rani Therapeutics Holdings, Inc. Announces Appointment of Nicholas Maestas as Chief Financial Officer, Effective June 29, 2026 - marketscreener.com

Jun 29, 2026

Rani Therapeutics names Nicholas Maestas as CFO - Investing.com

Jun 29, 2026

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - GlobeNewswire

Jun 29, 2026

Jun 28, 2026

Price to earnings forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - TradingView

Jun 28, 2026

Jun 26, 2026

Rani Therapeutics Holdings, Inc. Class A Actuals & Estimates (NASDAQ:RANI) - TradingView

Jun 26, 2026

Jun 25, 2026

RANI Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026